Related Experiment Video
Updated: Jul 17, 2026
10:07
High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels
Published on: January 27, 2013
Evaluation of Novel Cloxyquin Analogs for K2P18.1 Channel Modulation
Jasmin Sörgel1, Marcel Kloth2, Henning Klaasen2
1Institute of Pharmaceutical and Medicinal Chemistry, University of Münster, Münster, NRW, Germany.
Archiv Der Pharmazie
|July 16, 2026
Summary
Researchers explored new activators for the K2P18.1 (TRESK) channel, crucial for neurological and immune diseases. A novel benzaldimine derivative, 3d, unexpectedly enhanced channel activity, offering a new scaffold for drug development.
Area of Science:
- Neuroscience
- Pharmacology
- Molecular Biology
Background:
- K2P18.1 (TRESK) is an unusual potassium channel implicated in neurological and immune disorders.
- Existing K2P18.1 activators like cloxyquin have limitations due to side effects associated with their 8-hydroxyquinoline structure.
- The 8-OH group is essential for activation, but alternative substitutions are sought to improve safety profiles.
Purpose of the Study:
- To synthesize and evaluate novel quinoline derivatives as potential K2P18.1 channel modulators.
- To identify compounds with improved safety profiles compared to existing 8-hydroxyquinolines.
- To explore new chemical scaffolds for K2P18.1 channel activator development.
Main Methods:
- Synthesis of 14 novel quinoline derivatives with substitutions at the 8-position.
- Two-electrode voltage clamp (TEVC) electrophysiology to determine channel activity.
- In silico molecular docking studies to predict binding interactions.
- Assessment of compound stability in aqueous solutions.
Main Results:
- Four derivatives exhibited moderate K2P18.1 inhibitory or stimulatory activity.
- Benzaldimine 3d, a novel extended scaffold, unexpectedly increased K2P18.1 channel activity by approximately 60% at 100 µM.
- Docking studies indicated that 3d interacts with key amino acids in the cloxyquin binding site.
- Compound 3d demonstrated limited in vitro usability due to hydrolysis, with a half-life of 39 minutes.
Conclusions:
- The study identified a new scaffold (benzaldimine) for K2P18.1 channel activators.
- Compound 3d represents a promising starting point for developing novel K2P18.1 modulators with potentially improved therapeutic applications.
- Further diversification of this scaffold is warranted to optimize activity and stability for therapeutic use.
Related Concept Videos
01:18Patch Clamp
Many fundamental cell functions such as muscle contraction and nerve transmission rely on the electrical signals produced by the movement of positively and negatively charged ions across the cell membrane. One competent method to record current flowing across the whole cell or single ion channel is the patch-clamp technique.
In this method, a glass micropipette containing electrolyte solution is tightly sealed against a small portion of the cell membrane. As a result, a patch of the cell...
In this method, a glass micropipette containing electrolyte solution is tightly sealed against a small portion of the cell membrane. As a result, a patch of the cell...
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...